A rod-like nanoparticle drug delivery system for hydrophilic small molecules

Unmet Need

New strategies to load small molecule drugs into nanoparticles are a powerful approach to improve the therapeutic efficacy of chemotherapeutics, and this has been a successful strategy for overcoming the limitations of poor drug solubility with hydrophobic drugs. While the delivery of hydrophobic drugs remains the most common target when designing nanoparticles, hydrophilic drugs also suffer from rapid renal clearance and premature *in vivo* degradation. Because of these limitations, multiple high-dose injections of hydrophilic chemotherapeutics are necessary to attain a therapeutically relevant concentration in a tumor, but the maximum dose is limited by systemic side effects to healthy organs. Hence, better methods to deliver hydrophilic chemotherapeutics are needed.


Technology

Duke inventors have reported a nanoparticle drug delivery system intended to improve the therapeutic efficacy of hydrophilic chemotherapeutics. This is a recombinant asymmetric triblock peptide (ATBP) that self-assembles into rod-shaped nanoparticles which can then be used to conjugate diverse hydrophilic molecules. The polypeptides exhibit lower critical solution temperature phase behavior, enabling them to form gel-like depots that increase the half-life of their cargo. Mouse studies have demonstrated significantly longer plasma half-life and better antitumor efficacy using gemcitabine loaded ATBP.

Other Applications

This technology can also be used to improve delivery of hydrophilic imaging agents.

Advantages



Duke File (IDF) Number

IDF #:T-005023

Patent Information

Patent #: 11,135,301 Patent Title: TRIBLOCK POLYPEPTIDE-BASED NANOPARTICLES FOR THE DELIVERY OF HYDROPHILIC DRUGS Country United States of America

Meet the Inventors

<u>Chilkoti, Ashutosh</u> Bhattacharyya, Jayanta

Contact For More Info

Rasor, Robin (919) 681-6412 robin.rasor@duke.edu

Department

Biomedical Engineering (BME)

Publication(s)

•

External Link(s)

• From the lab of Dr. Ashutosh Chilkoti

- This technology can improve the delivery of hydrophilic small molecule drugs
- Improved plasma-half life and enhanced tumor accumulation demonstrated in animal studies
- Can deliver a wide range of hydrophilic molecules